Liso-Cel in B-Cell Lymphomas in TRANSFORM Study With Dr. Kamdar

During the 2024 ASCO^® Annual Meeting, Blood Cancers Today spoke with Manali Kamdar, MD, of University of Colorado, to hear results from the pivotal phase III TRANSFORM study on lisocabtagene maraleucel (liso-cel) versus standard of care in patients with relapsed or refractory large B-cell lymphoma (LBCL).

Dr. Kamdar first outlined the results of previous analyses in TRANFORM and noted that the US Food and Drug Administration approved liso-cel for second-line therapy in high-risk relapsed or refractory LBCL based on these interim analyses.

“In the [first] prespecified interim analysis at 6.2 months median follow-up, the TRANFORM study met its primary endpoint, which was event-free survival (EFS),” Dr. Kamdar said. “EFS was statistically significant and superior in the liso-cel arm versus standard of care.”

Liso-cel was also associated with statistically significantly higher complete response rates and progression-free survival (PFS) versus standard of care, according to Dr. Kamdar.

“The primary analysis of the TRANSFORM study after a median follow-up of 17.5 months confirmed the superior efficacy as well as safety of liso-cel over standard of care in this high-risk patient population,” Dr. Kamdar stated.

The presentation at the 2024 ASCO® Annual Meeting included the results of analyses after a median follow-up of 33.9 months.

In this analysis, the median EFS was 29.5 months with liso-cel compared with 2.4 months with standard of care.

“This translated into a stratified hazard ratio of .37 and a 36-month EFS rate for the liso-cel arm of 45.8% versus 19% in the standard of care arm,” Dr. Kamdar reported. She added that complete response rates have continuously been higher with liso-cel versus standard of care.

“The safety results remain consistent with the prior primary analysis and thus liso-cel second-line treatment in patients with primary refractory or early-relapse LBCL continues to show evidence for long-term disease control and curative potential,” Dr. Kamdar closed.